In the late 1990's Celera was the main contributor to cutting edge science for the 'Genome Project'. In 2011 Celera was bought for 344 MIL by Quest Diagnostics. At the time there was a conflict in that The NIH and contributors on the project basically said that genes couldn't be patented. This obviously is not in question since stem cell lines can be patented.
Biotime's LifeMap is possibly along the same lines following in Celera's foot steps. Biotime's mapping of the embryome, bio informatics and human disease is in many ways just as important as the initial genome mapping project.Nobody has such extensive inclusive database that i am aware of, and nobody has the body hESC lines Biotime has. Certainly the gold standard and when scientists need a reference, this will be it.
Now the question is money. Will LifeMap be able to make sufficient revenue on worldwide subscriptions of their databases? Revenue will surely increase but this is not the point here, one has to look at the big picture. By acquiring Lifemaps Biotime has now has the vehicle for presenting their products. Biotime behind the scenes has been patenting every hESC progenitor cells that exists in the body.
LifeMap IPO in a year or two will give Biotime the option to sell. Depends on which focus they want to be their bread and butter. OncoCyte(Cancer/cancer detection)? LifeMaps?, ReCyte? OrthoCyte?
As these subsidiaries grow, the option to sell one becomes a reality giving BTX the $ needed to continue on alone without sharing profits with big pharma.